Olema Pharmaceuticals (OLMA) Projected to Post Earnings on Wednesday

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.52) per share for the quarter.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.12. On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $4.60 on Wednesday. The company has a market capitalization of $314.46 million, a P/E ratio of -2.10 and a beta of 2.03. Olema Pharmaceuticals has a 52-week low of $2.86 and a 52-week high of $16.62. The business has a 50-day simple moving average of $4.25 and a two-hundred day simple moving average of $6.48.

Analyst Ratings Changes

OLMA has been the topic of a number of recent analyst reports. Oppenheimer reiterated an "outperform" rating and set a $25.00 target price (down from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday, March 19th. JPMorgan Chase & Co. decreased their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, March 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a research note on Monday, April 28th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.